Skip to content
MarketScale
‹ Back to Industries

Sciences

This Season’s Mission Will Be Making Space Relatable

Space to Grow is back for a second season with hosts Chris Blackerby and Charity Weeden from Astroscale. It’s where economics, technology and sustainability in space intersect. In the opening episode, Blackerby and Weeden take a look back and forward regarding the space economy. “We’re going to focus a lot on partnerships as a dedicated…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · AstroscaleJames Webb Space TelescopePartnershipsPolicy
Share

Key takeaways

01

Space to Grow is back for a second season with hosts Chris Blackerby and Charity Weeden from Astroscale.

02

It’s where economics, technology and sustainability in space intersect.

03

In the opening episode, Blackerby and Weeden take a look back and forward regarding the space economy.

Space to Grow is back for a second season with hosts Chris Blackerby and Charity Weeden from Astroscale. It’s where economics, technology and sustainability in space intersect. In the opening episode, Blackerby and Weeden take a look back and forward regarding the space economy.

“We’re going to focus a lot on partnerships as a dedicated theme of conversations, as they are driving the space economy,” Blackerby said.

Since space exploration and sustainability are such complex initiatives, partnerships are critical.

Blackerby and Weeden shared some big moments in space from the last year. “Even with COVID, it was an incredible year for space,” Blackerby noted.

Weeden’s top moment was humanity in space. “Private citizens went into space. That’s a first, and everyone can relate to that.”

While that was a pivotal moment, others demonstrated risks and challenges, spawning from geopolitical impacts on Earth. One of those is the Russian ASAT (anti-satellite weapon) tests.

Turning back to good news that demonstrates cooperation and collaboration, the James Webb Space Telescope launched through a partnership between the U.S. and Europe. Weeden relayed that the investment in the space economy isn’t slowing in other good news. It’s actually growing.

The hosts then provided a preview of what’s to come this season. They’ll welcome a diverse group of guests from around the world. Topics will range from business to policy to technology.

Weeden also announced a new segment Space to Grow After Hours. “We’ll be debating topics with the pros and cons in this extra content,” she described.

More in This Series

About the author

CB
Chris Blackerby

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby